Almiral: Main Uses and Benefits

Almiral (Diclofenac) is relevant in clinical settings where supportive symptomatic relief is needed for conditions involving symptoms that interfere with daily functioning and symptoms related to inflammatory or irritative states. This medicine is used for the relief of pain and inflammation in a wide range of conditions, and is considered relevant within therapeutic areas involving arthritic and acute musculoskeletal disorders.

The medication is applied across domains where additional symptomatic support is needed for certain distressing symptoms. It is commonly used across conditions characterized by periods of heightened symptoms such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Almiral is also relevant for easing symptoms that become more disruptive during flare-ups of gout, migraine headaches, or primary dysmenorrhea, and for pain following sprains or trauma. This support helps ease the overall symptom burden and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Pain and Inflammation
Therapeutic Relevance	Symptoms related to inflammatory or irritative states
Primary Support	Contributes to improved comfort and eases overall symptom load
Use Context	Acute episodic flares and chronic symptomatic support

Eligibility Map: Who can and cannot use Almiral — Official Regulatory Information

Official labeling for Almiral (Diclofenac Sodium) strictly defines the patient populations permitted to use the medicine and those who are excluded due to regulatory contraindications.

---

Eligibility Status	Population/Condition
Absolute Contraindications	History of allergic reactions (including asthma or urticaria) to any NSAID or aspirin.	Treatment of pain following Coronary Artery Bypass Graft (CABG) surgery.	Established severe heart failure (NYHA Class II-IV) or major vascular disease (Ischaemic Heart Disease, Cerebrovascular Disease).	Active gastrointestinal ulceration, bleeding, or perforation.	Severe renal or hepatic impairment.
Use Restricted/Caution	Geriatric patients (use lowest effective dose).	Patients with mild-to-moderate renal or hepatic impairment.	Patients with cardiovascular risk factors (e.g., hypertension, hyperlipidaemia).
Age-Related Rules	Standard oral tablets are typically not recommended for children under 14 years of age. Adult use is standard.
Reproductive Status	Contraindicated at or after 30 weeks gestation in pregnancy; use before this time is restricted to the lowest dose for the shortest duration possible. Not recommended during breastfeeding or for women attempting to conceive.

---

Official regulatory documents establish Almiral's eligibility by classifying absolute contraindications based on a patient's history of NSAID allergy, current status of major organ function, and late-stage pregnancy. The use is allowed primarily for adults, while limitations are placed on pediatric age groups and those with pre-existing risk factors, necessitating cautionary use.

Interactions with other medicines and products

The regulatory interaction profile for Almiral (Diclofenac Sodium) is defined by documented restrictions and the potential for clinically significant drug-drug interactions.

---

Formal Restrictions and Contraindications

Almiral is formally contraindicated for the treatment of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. It is also contraindicated in patients who have experienced allergic reactions, such as asthma or urticaria, following the use of aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

---

Pharmacodynamic and Exposure Interactions

The profile is dominated by additive pharmacodynamic risks. Co-administration with anticoagulants, SSRIs, oral corticosteroids, or alcohol significantly increases the documented risk of serious gastrointestinal adverse events, including bleeding.

Furthermore, Almiral may diminish the antihypertensive and natriuretic effects of ACE Inhibitors, ARBs, and Diuretics. Regarding exposure modification, Almiral may cause an increase in the plasma concentrations of co-administered medicines such as Lithium, Methotrexate, and Digoxin, typically by reducing their renal or metabolic clearance. Conversely, strong inhibitors of the CYP2C9 enzyme are documented to increase the overall systemic exposure of Almiral itself.

---

Population-Specific Notes

Regulatory documentation notes that elderly patients are at a greater risk for serious gastrointestinal adverse events, an effect compounded by interacting substances. Additionally, high-risk patients, including the elderly or those with underlying renal impairment, are at increased risk of renal function deterioration when Almiral is combined with ACE Inhibitors or ARBs.

How Almiral Works — Mechanism of Action

Diclofenac Sodium (Almiral) acts primarily by targeting and inhibiting the Cyclooxygenase (COX) enzyme system. This selective molecular interference results in changes to physiological processes across several systems.

---

Targeting the Prostanoid Synthesis Pathway

This mechanistic domain covers the drug's core action of inhibiting the COX-1 and COX-2 enzymes, which are critical catalysts in the lipid-signaling cascade. By preventing these enzymes from converting arachidonic acid into prostaglandins and other prostanoids, the molecule suppresses the synthesis of mediators involved in the inflammatory response.

---

Modulation of Inflammatory Mediators and Nociception

The reduction in prostaglandin synthesis is the key step that leads to a change in two major physiological processes. Peripherally, lower levels of PGE2 decrease the sensitization of pain receptors in damaged tissues, thereby modulating the transmission of nociceptive signals. Centrally, the suppression of PGE2 production in the hypothalamus allows for the recalibration of the body's elevated temperature set point.

---

️ Mechanistic Specificity and Physiological Constraints

Diclofenac exhibits a preferential inhibitory effect on COX-2, the enzyme primarily induced during inflammation, while also inhibiting COX-1, which is involved in vital maintenance functions. This reliance on enzyme inhibition inherently limits the physiological processes that depend on constitutive COX-1 activity. The effects on the central nervous system's thermoregulatory center establish a full mechanistic scope across pain signaling, inflammation, and temperature.

How to Use Almiral (Diclofenac): Official Administration Guidelines

The usage of systemic Almiral (Diclofenac) is strictly guided by the principle of administering the lowest effective dose for the shortest duration necessary. The medicine is available in multiple official forms, each with specific administration requirements.

Official Routes and Dosing

Administration Route	Standard Adult Dosing Principles	Specific Use Constraints
Oral (Delayed-Release, Extended-Release Tablets)	For chronic conditions, typical maintenance is 50 mg to 75 mg two to three times daily, or 100 mg extended-release once daily. Max dose is generally 150 mg per day.	Tablets must be swallowed whole and not crushed, split, or chewed to preserve the intended release profile.
Oral (Powder for Solution)	Used as a single 50 mg dose for acute situations (e.g., migraine).	Must be mixed with only 30 mL to 60 mL of plain water and consumed immediately, typically on an empty stomach.
Parenteral (IM/IV Injection)	75 mg dose, which may be repeated once. Max daily dose is 150 mg.	Parenteral use is generally restricted to a maximum of two days before switching to an oral form. IV infusion requires dilution with buffered saline or glucose solution and must be administered over a specific duration (e.g., 30 minutes to 2 hours).
Topical (Gel/Solution/Patch)	Applied directly to the affected area, usually three to four times daily for the gel.	Application is for local use; dosage adjustment is generally not required for mild-to-moderate renal or hepatic impairment when using systemic forms, but caution and the lowest dose are advised for all populations, including older adults.

General Procedural Rule

Different oral formulations (e.g., immediate-release, delayed-release, extended-release) are not bioequivalent and should not be interchanged without specific instruction. If a dose is missed, the general guidance is to take it as soon as remembered, unless it is near the time for the next dose, in which case the missed dose should be skipped; do not double the dose.

Research evidence / Overview of Studies for Almiral (Diclofenac)

---

Evidence for Use in Chronic Joint Conditions (Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis)

Research exploring the medicine's role in chronic joint symptoms has utilized short-term Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews and Meta-Analyses in research exploring the medicine's effect on chronic symptoms of pain and inflammation. These studies were used in research exploring how symptoms change over time in adult populations with diagnosed conditions like osteoarthritis (OA) and rheumatoid arthritis (RA), and ankylosing spondylitis. The outcomes primarily monitored included outcomes related to physical discomfort, scores for physical function and daily activity level, and measurements of joint stiffness and swelling.

Findings describe patterns observed in the studies in the treatment group and the control groups, including those receiving placebo or vehicle. Research highlights changes measured during the study period for outcomes linked to inflammatory or irritative states. Research has explored both oral and topical formulations for conditions like OA.

---

Evidence for Use in Acute Pain and Inflammation

Research has explored conditions characterized by acute or disruptive episodes, such as acute musculoskeletal injuries, post-operative pain, and primary dysmenorrhea, primarily using short-term RCTs. Studies focused on episodes where symptoms become more noticeable, measuring outcomes related to physical discomfort and outcomes describing episodic changes, such as the use of supplemental pain medication.

Findings describe patterns observed in the studies related to pain intensity that were recorded during the short observation intervals. Research indicates that the outcomes monitored in post-operative settings monitored the amount of supplemental pain medication used and pain scores in the immediate recovery period. Because these conditions are temporary, the research typically focused on very short-term observation periods, often only a few days to a few weeks. The evidence base for this specific acute use is considered established.

---

What is Still Uncertain About the Research

Scientific reviews indicate that key limitations exist within the overall evidence base. Follow-up durations were limited across many trials, which creates limited information for long-term outcomes and the consistency of symptomatic patterns. Additionally, certain aspects of the evidence quality vary across studies, particularly when comparing older, historical trials with modern designs.

Data for certain groups remain insufficient; for instance, comprehensive long-term evidence in young adults or those with specific, rare comorbidities is often lacking. The research primarily describes group responses, and comparative evidence against all available treatment options is always evolving or lacking in head-to-head trials for all specific symptomatic outcomes.

Key Studies & References

1. Efficacy and safety of over-the-counter analgesics for primary dysmenorrhea - A network meta-analysis

Storage and Protection Requirements

Almiral must be stored in specific environmental conditions to maintain its quality. Tablets and injection solutions are typically required to be stored below 30°C and must be kept in the original container to be protected from light and moisture. Furthermore, the container must remain tightly closed.

All Almiral formulations must be kept out of the sight and reach of children and stored in a secure, locked-up location. For the injectable solution, any remaining product in an opened ampoule must be discarded immediately and not reused.

Disposal Instructions

Unused or expired Almiral must not be disposed of in general household waste or wastewater, as this can contaminate the environment. Disposal must be managed safely in accordance with local requirements by returning the product to a pharmacy or an approved waste disposal collection point.